CBDV (cannabidivarin)

Cannabidivarin (CBDV) represents another non-intoxicating cannabinoid that appears most prevalently in CBD-dominant cannabis chemovars. Though research into CBDV remains in early stages, initial small preclinical studies suggest it too may offer a wide spectrum of promising therapeutic benefits similar to CBD. Most prominently, CBDV’s apparent anti-nausea and vomiting effects make it an especially promising therapeutic option for providing relief to chemotherapy patients. CBDV also demonstrates potential in models of some childhood epilepsy disorders for improving behaviors and symptoms associated with autism, as well as appearing to benefit patients specifically with Rett Syndrome. Additionally, CBDV exhibits measurable anti-inflammatory properties that can help restore normal mobility and lost muscle function in animal models of Duchenne muscular dystrophy. While still highly preliminary, these early exploratory research findings underscore the critical importance of continuing to push forward investigations delving deeper into CBDV and the other numerous minor cannabis constituents beyond the major players.